BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15668707)

  • 41. Relationship Between the Expression of O
    Vitellius C; Eymerit-Morin C; Luet D; Fizanne L; Foubert F; Bertrais S; Rousselet MC; Caroli-Bosc FX
    Clin Drug Investig; 2017 Jul; 37(7):669-677. PubMed ID: 28421382
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage I-II colon cancer patients.
    Huang SC; Huang SF; Chen YT; Chang Y; Chiu YT; Chang IC; Wu HI; Chen JS
    Biomed J; 2017 Feb; 40(1):39-48. PubMed ID: 28411881
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.
    Liu G; Pei F; Yang F; Li L; Amin AD; Liu S; Buchan JR; Cho WC
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer.
    Mármol I; Sánchez-de-Diego C; Pradilla Dieste A; Cerrada E; Rodriguez Yoldi MJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106826
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.
    Du L; Kim JJ; Shen J; Chen B; Dai N
    Oncotarget; 2017 Mar; 8(13):22175-22186. PubMed ID: 28077799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Relevance and Molecular Phenotypes in Gastric Cancer, of TP53 Mutations and Gene Expressions, in Combination With Other Gene Mutations.
    Park S; Lee J; Kim YH; Park J; Shin JW; Nam S
    Sci Rep; 2016 Oct; 6():34822. PubMed ID: 27708434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy.
    Yu JI; Lee H; Park HC; Choi DH; Choi YL; Do IG; Kim HC; Lee WY; Yun SH; Cho YB; Huh JW; Park YA; Park YS; Park JO; Kim ST; Park W
    Oncotarget; 2016 Sep; 7(38):62676-62686. PubMed ID: 27391438
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
    Kandioler D; Mittlböck M; Kappel S; Puhalla H; Herbst F; Langner C; Wolf B; Tschmelitsch J; Schippinger W; Steger G; Hofbauer F; Samonigg H; Gnant M; Teleky B; Kührer I;
    EBioMedicine; 2015 Aug; 2(8):825-30. PubMed ID: 26425688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancer.
    Jorissen RN; Christie M; Mouradov D; Sakthianandeswaren A; Li S; Love C; Xu ZZ; Molloy PL; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Burgess AW; Busam D; Zhao Q; Strausberg RL; Lipton L; Desai J; Gibbs P; Sieber OM
    Br J Cancer; 2015 Sep; 113(6):979-88. PubMed ID: 26305864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.
    Salnikova LE; Kolobkov DS
    Pharmacogenomics J; 2016 Jun; 16(3):249-65. PubMed ID: 26122021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays.
    Stahl PR; Schnellert J; Koop C; Simon R; Marx A; Izbicki JR; Sauter G; Quaas A
    Pathol Oncol Res; 2015 Sep; 21(4):1183-9. PubMed ID: 26026893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
    Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
    Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathological analysis of factors related to colorectal tumor perforation: influence of angiogenesis.
    Medina-Arana V; Martínez-Riera A; Delgado-Plasencia L; Rodríguez-González D; Bravo-Gutiérrez A; Álvarez-Argüelles H; Alarcó-Hernández A; Salido-Ruiz E; Fernández-Peralta AM; González-Aguilera JJ
    Medicine (Baltimore); 2015 Apr; 94(15):e703. PubMed ID: 25881846
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer.
    Wei XL; Wang DS; Xi SY; Wu WJ; Chen DL; Zeng ZL; Wang RY; Huang YX; Jin Y; Wang F; Qiu MZ; Luo HY; Zhang DS; Xu RH
    World J Gastroenterol; 2014 Dec; 20(48):18404-12. PubMed ID: 25561809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.
    Shi Y; Han Y; Xie F; Wang A; Feng X; Li N; Guo H; Chen D
    J Cell Mol Med; 2015 Mar; 19(3):535-43. PubMed ID: 25534115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives.
    Chen GX; Zhang S; He XH; Liu SY; Ma C; Zou XP
    Onco Targets Ther; 2014; 7():1901-9. PubMed ID: 25364261
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishment of new predictive markers for distant recurrence of colorectal cancer using lectin microarray analysis.
    Nakajima K; Inomata M; Iha H; Hiratsuka T; Etoh T; Shiraishi N; Kashima K; Kitano S
    Cancer Med; 2015 Feb; 4(2):293-302. PubMed ID: 25355679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.
    Tornesello ML; Annunziata C; Buonaguro L; Losito S; Greggi S; Buonaguro FM
    J Transl Med; 2014 Sep; 12():255. PubMed ID: 25220666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA methylation of apoptosis genes in rectal cancer predicts patient survival and tumor recurrence.
    Benard A; Zeestraten EC; Goossens-Beumer IJ; Putter H; van de Velde CJ; Hoon DS; Kuppen PJ
    Apoptosis; 2014 Nov; 19(11):1581-93. PubMed ID: 25064172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.
    Lee KH; Park JW; Sung HS; Choi YJ; Kim WH; Lee HS; Chung HJ; Shin HW; Cho CH; Kim TY; Li SH; Youn HD; Kim SJ; Chun YS
    Oncogene; 2015 May; 34(22):2897-909. PubMed ID: 25043306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.